Objectif
Partners come from 10 European countries to achieve two main objectives: A) The further exploration of 3 animal models (the OBX rat, GS rat and NOD mouse) characterized by an activated immune response system (IRS), an abnormal tryptophan catabolism and a depressive-like behaviour to study the pathogenesis of inflammation-related mood disorders and the efficacy/working mechanism of anti-inflammatory and tryptophan metabolism restoring drugs. B) The in-parallel study of mood disorder patients to validate two sets of already developed biomarker tests to identify patients and individuals at risk for a mood disorder and characterized by an activated IRS to be able to treat these patients/individuals with drugs counteracting the consequences of the activated IRS/disturbed catabolism of tryptophan. Five strategic approaches (broken down in 12 workpackages) are used: 1) Study of the animal models for depressive-like behavior and aberrancies in monocytes/ macrophages, the tryptophan metabolism and the microglia-astrocyte-neuron interaction. 2/3) The validation of a high-throughput biomarker mRNA blood monocyte signature test and a biomarker test to detect an abnormal tryptophan catabolism. 4) Correlation studies between the outcomes of these biomarker tests in patients to various clinical variables, a.o. gene polymorphisms and the brain scan. 5) The therapeutic targetting of the activated IRS/abnormal tryptophan catabolism using a PDE4 inhibitor, a COX-2 inhibitor and a KMO-inhibitor in the animal models and in a phase II intervention study in depressed patients. Novel approaches are the prospective assessment of patients/individuals to identify whether changes in the IRS have any prognostic value and that the program aims at a personalized treatment of patients on the basis of their activated IRS. We heavily rely in this on the study of the animal models, which allow us to test anti-inflammatory therapeutics and to know their mechanism of action at the brain.
Champ scientifique
Thème(s)
Appel à propositions
FP7-HEALTH-2007-B
Voir d’autres projets de cet appel
Régime de financement
CP-IP - Large-scale integrating projectCoordinateur
3015 GD Rotterdam
Pays-Bas
Voir sur la carte
Participants (20)
80539 MUNCHEN
Voir sur la carte
48149 MUENSTER
Voir sur la carte
9713 GZ Groningen
Voir sur la carte
6020 Innsbruck
Voir sur la carte
3000 Leuven
Voir sur la carte
WC2R 2LS London
Voir sur la carte
20132 MILANO
Voir sur la carte
1463 Sofia
Voir sur la carte
D02 CX56 DUBLIN 2
Voir sur la carte
BD7 1DP Bradford
Voir sur la carte
75654 Paris
Voir sur la carte
20100 Rozzano (Mi)
Voir sur la carte
751 05 Uppsala
Voir sur la carte
Participation terminée
3051 HM ROTTERDAM
Voir sur la carte
2300 Turnhout
Voir sur la carte
82152 Martinsried
Voir sur la carte
20091 BRESSO
Voir sur la carte
79106 Freiburg
Voir sur la carte
3584 CX Utrecht
Voir sur la carte
20132 Milano
Voir sur la carte